Revenue of $231.3 million. Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share. Adjusted Net Income2 of $24.4 million; $0.11 ...
Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...
(“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in ...